Company intelligence
HQ Science
Get molecular diagnostics within hours, not weeks
About HQ Science
HQ Science is an Oxford-based MedTech company backed by the UK Health Security Agency, developing a point-of-care molecular diagnostics platform that delivers results in hours instead of weeks. By combining real-time transcriptomic analysis with scalable AI-driven diagnostics, we are enabling faster, more accessible precision medicine across oncology, sepsis, and emergency care, in partnership with leading institutions including the NHS, Oslo University Hospital, and the Oscar Lambret Centre.
Verified activity
Signals from HQ Science
6 published signals
Research & Knowledge
HQ Science noted that the validation manuscript for the Menopause Impact Scale is still in peer review.
Reported by Alex Diatlov
Products & Services
HQ Science distributed the Menopause Impact Scale into ten healthcare partners including Alloy, Gennev, Maven, Tia, Hertility, and five more.
Reported by Alex Diatlov
Partnerships
HQ Science partnered with WHOOP to pay for one of the routes into women’s health.
Reported by Alex Diatlov
Capital & Finance
HQ Science reports that Moderna added $45B in market cap on a cancer vaccine.
Reported by Alex Diatlov
Capital & Finance
HQ Science reports that BioNTech stopped its own trial nine days later.
Reported by Alex Diatlov
Legal & Regulatory
HQ Science announced that the FDA approved a first-of-its-kind pancreatic cancer drug in 35 days through the new priority-review programme.
Reported by Alex Diatlov